BUCHANG PHARMA(SH:603858) Shang Hai Zheng Quan Bao·2026-02-09 17:58Core Viewpoint - The company has agreed to waive its right of first refusal on a 1% unpaid equity stake in its subsidiary, Shandong Buchang Guanyou Medical Equipment Co., Ltd., which will be transferred to Zhu Binbin for a price of RMB 0, maintaining the company's 90% ownership stake in the subsidiary [2][4]. Group 1: Transaction Overview - The transaction involves the transfer of a 1% unpaid equity stake in Buchang Guanyou from shareholder Liu Anan to Zhu Binbin, with the company waiving its right of first refusal [2][4]. - The board of directors approved the transaction on February 6, 2026, and it does not require shareholder approval as it does not constitute a related party transaction or a major asset restructuring [2][4][10]. - The transaction is free from significant legal obstacles and will not affect the company's consolidated financial statements or operational results adversely [3][10]. Group 2: Basic Information of the Transferee - Zhu Binbin is currently the Director of the Sales Department at Buchang Guanyou [5]. Group 3: Basic Information of the Target Company - Shandong Buchang Guanyou Medical Equipment Co., Ltd. is a limited liability company with a registered capital of RMB 5 million [6]. - As of September 30, 2025, the company reported total assets of RMB 121,508.66, total liabilities of RMB 82,214.63, and a net asset of RMB 39,294.03, with a net loss of RMB 85,705.97 for the first nine months of 2025 [7]. Group 4: Pricing and Impact on the Company - The transaction price was determined through negotiation and is considered fair and reasonable, complying with relevant laws and regulations [9]. - The decision to waive the right of first refusal aligns with the company's overall strategic development and will not negatively impact its financial status or future operational results [10].